The Lipid lowering and Onset of Renal Disease (LORD) Trial: A randomized double blind placebo controlled trial assessing the effect of atorvastatin on the progression of kidney disease
Open Access
- 18 March 2008
- journal article
- research article
- Published by Springer Science and Business Media LLC in BMC Nephrology
- Vol. 9 (1), 4-6
- https://doi.org/10.1186/1471-2369-9-4
Abstract
No abstract availableKeywords
This publication has 27 references indexed in Scilit:
- Statistics in Medicine — Reporting of Subgroup Analyses in Clinical TrialsThe New England Journal of Medicine, 2007
- Effect of Intensive Lipid Lowering with Atorvastatin on Renal Function in Patients with Coronary Heart DiseaseClinical Journal of the American Society of Nephrology, 2007
- Insulin Resistance, Oxidative Stress, and Podocyte Injury: Role of Rosuvastatin Modulation of Filtration Barrier InjuryAmerican Journal of Nephrology, 2007
- Rosuvastatin Treatment Prevents Progressive Kidney Inflammation and Fibrosis in Stroke-Prone RatsThe American Journal of Pathology, 2007
- Study of Heart and Renal Protection (SHARP)Kidney International, 2003
- The effects of an ACE inhibitor and a calcium antagonist on the progression of renal disease: the Nephros StudyNephrology Dialysis Transplantation, 2001
- Effect of simvastatin on renal function in autosomal dominant polycystic kidney diseaseNephrology Dialysis Transplantation, 2001
- Effect of lipid reduction on the progression of renal disease: A meta-analysisKidney International, 2001
- Doubling of serum creatinine: is it sensitive and relevant?Nephrology Dialysis Transplantation, 1998
- Effects of dietary protein restriction on the progression of advanced renal disease in the modification of diet in renal disease studyAmerican Journal of Kidney Diseases, 1996